Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

791
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
791
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.4K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.4K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

580
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
580
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Lesion Morphology and Resection Strategy on Curative Outcomes in Colorectal Malignant Polyps.

Clinical colorectal cancer·2026
Same author

Colonic Leishmaniasis Mimicking a Malignant Stricture: Initial Presentation of Human Immunodeficiency Virus Infection - A Case Report.

GE Portuguese journal of gastroenterology·2026
Same author

Early identification of patients with steatotic liver disease: Prospective evaluation of attenuation coefficient as an add-on to B-mode ultrasound.

European journal of radiology·2026
Same author

Concordance Between Pan-Intestinal Capsule Endoscopy and Colonoscopy for the Detection and Characterization of Colonic Lesions: Post Hoc Analysis on the Impact of Colonic Transit Time.

Journal of gastroenterology and hepatology·2026
Same author

Not every stomach is the same: tailoring dysplastic and early gastric cancer lesions detection.

European journal of gastroenterology & hepatology·2026
Same author

Use of Intestinal Ultrasound in a Tight Monitoring Approach in Crohn's Disease: A Multicenter Prospective Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Mar 8, 2026

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

5.1K

Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Pedro Boal Carvalho1, José Cotter2,3,4

  • 1Hospital da Senhora da Oliveira-Guimarães, Rua dos Cutileiros, Creixomil, 4831-044, Guimarães, Portugal. pedroboalcarvalho@chaa.min-saude.pt.

Drugs
|January 13, 2017
PubMed
Summary

Achieving mucosal healing (MH) is vital for ulcerative colitis (UC) patients, reducing relapses and cancer risk. This review details drugs and methods to promote and define MH for better UC management.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.7K

Related Experiment Videos

Last Updated: Mar 8, 2026

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

5.1K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.7K

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease
  • Clinical Therapeutics

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease with significant patient morbidity and long-term risks, including colorectal cancer.
  • Mucosal healing (MH) is increasingly recognized as a critical treatment goal in managing UC patients.
  • Current UC management strategies aim to induce remission and prevent disease relapse.

Purpose of the Study:

  • To review endoscopic findings defining mucosal injury and MH in UC.
  • To evaluate current scoring systems for assessing MH.
  • To summarize evidence for approved UC drugs in achieving and maintaining MH.

Main Methods:

  • Review of endoscopic findings and scoring systems for UC.
  • Analysis of basic mechanisms of colonic injury and MH.
  • Comprehensive review of clinical evidence for approved UC therapies targeting MH.
  • Inclusion of pharmacokinetic data for anti-tumor necrosis factor (TNF)-α agents.

Main Results:

  • Approved drugs including salicylates, corticosteroids, calcineurin inhibitors, thiopurines, vedolizumab, and anti-TNFα agents demonstrate efficacy in achieving MH.
  • MH is associated with reduced clinical relapse, hospitalization, surgery, and lower rates of dysplasia and colorectal cancer.
  • A stricter definition of complete MH, combining endoscopic and histological data, is proposed as the preferred endpoint.

Conclusions:

  • Mucosal healing is a key therapeutic target in ulcerative colitis, significantly improving patient outcomes.
  • Various drug classes are effective in achieving MH, with anti-TNFα agents and vedolizumab playing important roles.
  • A comprehensive definition of complete MH is essential for optimizing long-term UC management and patient prognosis.